Periodontal Study On Imagenetix Compound 1-TDC Published In Journal Of Periodontology

Imagenetix, Inc. (OTC Bulletin Board:
IAGX), announced today the first scientific publication of a study that was
conducted on its proprietary compound, 1-TDC, for the prevention of
periodontal disease. The study which was conducted at Boston University was
published in the April 26th issue of The Journal of Periodontology and is
available online at joponline/loi/jop.



Commenting on the results of the study, Mr. William P. Spencer,
President of Imagenetix said, "We are excited with the results of this
study, which demonstrates the potential of our compound to become a major
breakthrough for the prevention of periodontal disease." According to the
American Academy of Periodontology over 50% of the adults over the age of
50 have periodontitis or periodontal diseases, which creates a potential
multi-billion market for a product developed from our compound. We have
recently submitted and received PRE-IND approval from the FDA to begin
Safety Studies.



1-TDC is a proprietary blend of esterified fatty acids that inhibits
many oral bacteria. Many of these bacteria have been identified with
causing local and systemic inflammation. The purpose of the study was to
investigate the effect of 1-TDC on Porphyromonas gingivalis (P. gingivalis)
induced periodontitis. Boston University researchers have established the
P. gingivalis-induced periodontitis model in rabbits and have extensively
investigated the relationship of P.gingivalis infection to inflammation.



The study was performed under the direction of Hatice Hasturk, D.D.S.,
Ph.D.; Boston University, Department of Periodontology and Oral Biology.
The study was conducted using a rabbit model established by Boston
University researchers. Experimental periodontitis was induced in New
Zealand white rabbits with silk sutures tied around the mandibular second
pre-molars bilaterally and P.gingivalis applied topically. The test agent
(1-TDC) was applied topically at concentrations of 1 mg/ml and 10 mg/ml
three times per week for six weeks. After six weeks, 1-TDC showed a
reduction of inflammation, cellular infiltration, connective tissue
destruction and bone loss when compared to the placebo. "While both test
concentrations exhibited benefit, 1-TDC given at 10 mg/ml offered the most
significant improvement compared to placebo," stated Dr. Hasturk. "The
opportunity for 1-TDC to reduce the likelihood for an individual for
developing periodontal disease is exciting as there are limited options for
treating periodontitis."



Mr. Spencer added, "The scientists at the Boston University, Goldman
School of Dental Medicine have done an excellent job guiding us through the
discovery process. This study forms the foundation for outlining the
efficacy of 1-TDC for the prevention of periodontal disease. I am happy to
report that Dr. Robert Hesslink, Director of Research & Development along
with our clinical sciences staff continue to achieve research milestones in
this novel form of treating periodontal diseases. We expect to report
additional developments in the near future."
















About Imagenetix



Based in San Diego, California, Imagenetix, (OTC Bulletin Board: IAGX)
is an innovator of scientifically tested, natural-based, proprietary
bioceutical products developed to enhance human health on a global basis.
Imagenetix develops, formulates and private-labels propriety
over-the-counter topical creams, skincare products and nutritional
supplements to be marketed globally through multiple channels of
distribution. In addition, the company develops patentable compounds for
entering into licensing agreements with pharmaceutical partners. Imagenetix
is the creator of Inflame Away(TM)- Celadrin(R), which has been clinically
tested to relieve osteoarthritis pain and significantly improve joint
health. For more information, please visit, imagenetix.



This document contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Such statements are
subject to risks and uncertainties that could cause actual results to vary
materially from those projected in the forward-looking statements. The
company may experience significant fluctuations in future operating results
due to a number of economic, competitive, and other factors, including,
among other things, the size and timing of customer contracts, new or
increased competition, changes in market demand, and seasonality of
purchases of the company's products and services. These factors and others
could cause operating results to vary significantly from those in prior
periods and those projected in forward-looking statements. Additional
information with respect to these and other factors, which could materially
affect the company and its operations, are included in certain forms the
company has filed and will periodically file with the Securities Exchange
Commission.


Imagenetix, Inc.

imagenetix